Sequence and structural characterization of tbnat gene in isoniazid-resistant Mycobacterium tuberculosis: Identification of new mutations

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 712, Issue 1-2, 2011, Pages 33-39

  Coelho, Millene Borges ^a   Costa, Elis Regina Dalla ^b   Vasconcellos, Sidra Ezídio Gonçalves ^c   Linck, Natali ^a   Ramos, Ricardo Martins ^a   Amorim, Hermes Luís Neubauer de ^a   Suffys, Philip Noel ^c   Santos, Adalberto Rezende ^c   Silva, Pedro Eduardo Almeida da ^d   Ramos, Daniela Fernandes ^d   Silva, Márcia Susana Nunes ^a,b   Rossetti, Maria Lucia Rosa ^a,b  

^a UNIVERSIDADE LUTERANA DO BRASIL   (Brazil)

^b State Foundation for Productivity and Research for Public Health   (Brazil)

^c INSTITUTO OSWALDO CRUZ   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

Author keywords

Drug resistance; Molecular modeling; Mutation; Mycobacterium tuberculosis; Structure function; Tbnat Polymorphism

Indexed keywords

ACETYL COENZYME A; ACYLTRANSFERASE; ISONIAZID;

AHPC GENE; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; BINDING AFFINITY; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME SPECIFICITY; GENE IDENTIFICATION; GENE MUTATION; GENE STRUCTURE; GENETIC ANALYSIS; INHA GENE; KATG GENE; MOLECULAR MODEL; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; TBNAT GENE; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG RESISTANCE, BACTERIAL; GENES, BACTERIAL; ISOENZYMES; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POLYMORPHISM, SINGLE NUCLEOTIDE;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79957684830     PISSN: 00275107     EISSN: 09218262     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2011.03.017     Document Type: Article

References (42)

1. Zhang Y., Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. Molecular Genetics of Mycobacteria 2000, 235-253. ASM Press, Washington DC. G.F. Hatfull, W.R. Jacobs (Eds.).
2. Timmins G.S., Deretic V. Mechanisms of action of isoniazid. Mol. Microbiol. 2006, 62:1220-1227.
3. Banerjee A., Dubnau E., Quemard A., Balasubramanian V., Um K.S., Wilson T., Collins D., Lisle G., Jacobs W.R. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 1994, 263:227-230.
4. Kelley C.L., Rouse D.A., Morris S.L. Analysis do ahpC gene mutations in isoniazid-reistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 1997, 41:2057-2058.
5. Mdluli K., Slayden R.A., Zhu Y., Ramaswamy S., Pan X., Mead D., Crane D.D., Musser J.M., Barry C.E. Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid. Science 1998, 280:1607-1610.
6. Lee A.S.G., Teo A.S.M., Wong S.Y. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 2001, 45:2157-2159.
7. van Rie A., Warren R., Mshanga I., Jordaan A.M., van der Spuy G.D., Richardson M., Simpson J., Gie R.P., Enarson D.A., et al. Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community. J. Clin. Microbiol. 2001, 39:636-641.
8. Rossetti M.L.R., Valim A.R.M., Silva M.S.N., Rodrigues V.S. Tuberculose resistente: revisão molecular. Rev. Saúde Pública 2002, 36:525-532.
9. Silva M.S.N., Senna S., Ribeiro M.O., Valim A.M., Telles M.A., Kritski A.L., Morlock G.P., Cooksey R.C., Zaha A., Rossetti M.L.R. Mutations in katG, inhA and ahpC genes of brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J. Clin. Microbiol. 2003, 41:4471-4474.
10. Dalla Costa E.R., Ribeiro M.O., Silva M.S.N., Arnold L.S., Rostirolla D.C., Cafrune P.I., Espinoza R.C., Palaci M., Telles M., Ritacco V., Suffys P.N., Lopes M.L., Campelo C.L., Miranda S.S., Kremer K., Silva Almeida P.E., Fonseca L.S., HO J.L., Kritski A.L., Rossetti M.L.R. Correlations of mutations in katG, oxyR-ahpC and inhA genes and in vitro susceptibility in Mycobacterium tuberculosis clinical strains segregated by spoligotype families from tuberculosis prevalent countries in South America. BMC Microbiol. 2009, 9:1-11.
11. Viveiros M., Leandro C., Amaral L. Mycobacterial efflux pumps and chemotherapeutic implications. Int. J. Antimicrob. Agents 2003, 22:274-278.
12. Upton A.M., Mushtaq A., Victor T.C., Sampson S.L., Sandy J., Smith D.M., van Helden P.D., Sim E. Arylamine N-acetyltransferase of Mycobacterium tuberculosis is a polymorphic enzyme and a site of isoniazid metabolism. Mol. Microbiol. 2001, 42:309-317.
13. Sholto-Douglas-Vernon C., Sandy J., Victor T.C., Sim E., van Helden P.D. Mutational and expression analysis of tbnat and its response to isoniazid. J. Med. Microbiol. 2005, 54:1189-1197.
14. Sandy J., Mushtaq A., Holton S.J., Schartau P., Noble M.E.M., Sim E. Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. 2005, 390:115-123.
15. Sim E., Westwood I., Fullam E. Arylamine N-acetyltransferases. Expert Opin Drug Metab. Toxicol. 2007, 3:169-184.
16. Fullam E., Westwood I.M., Anderton M.C., Lowe E.D., Sim E., Noble M.E. Divergence of cofator recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J. Mol. Biol. 2008, 375:178-191.
17. Sim E., Payton M., Noble M., Minchin R. An update on genetic, structural and functional studies of arylamine N-acetyltransferase in eucaryotes and prokaryotes. Hum. Mol. Genet. 2000, 9:2435-2441.
18. Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., Noble M. The structure of arylamine N-acetyltranferase from Mycobacterium smegmatis-an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 2002, 318:1071-1083.
19. Payton M., Auty R., Delgoda R., Everett M., Sim E. Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance. J. Bacteriol. 1999, 181:1343-1347.
20. Kent P.T., Kubica G.P. Public Health Mycobacteriology: A Guide for a Level III Laboratory 1985, Butterworth-Heinemann/Centers for Disease Control, Oxford, UK/Atlanta, GA, USA.
21. Canetti G., Fox W., Khomenko A., Mahler H.T., Menom N.K., Mitchison D.A., Rist N., Smeley N.A. Advancesin techniques of testing mycobacterial drug sensivity, and the use of sensivity tests in tuberculosis control programmes. Bull. WHO 1969, 41:21-43.
22. Palomino J.C., Martin A., Camacho M., Guerra H., Swings J., Portaels F. Resazurin microtiter assay plate: simple and inexpensive meted for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2002, 46:2720-2722.
23. van Soolingen D., de Haas P.E., Hermans P.W., van Embden J.D. DNA fingerprinting of Mycobacterium tuberculosis. Methods Enzymol. 1994, 235:196-204.
24. Telenti A., Honoré N., Bernasconi C., March J., Ortega A., Heym B., Takiff H.E., Cole S.T. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 1997, 35:719-723.
25. Otto T.D., Vasconcellos E.A., Gomes L.H.F., Moreira A.S., Degrave W.M., Mendonça-Lima L., Alves-Ferreira M. ChromaPipe: a pipeline for analysis, quality control and management for a DNA sequencing facility. Genet. Mol. Res. 2008, 7:861-871.
26. Kamerbeek J., Schouls L., Kolk A., van Agterveld M., van Soolingen D., Kuijper S., Bunschoten A., Molhuizen H., Shaw R., Goyal M., van J., Embden Simultaneous detection and strain differentiation of mycobacterium tuberculosis for diagnosis and epidemiology. J. Clin. Microbiol. 1997, 35:907-914.
27. Eswar N., Marti-Renom M.A., Webb B., Madhusudhan M.S., Eramian D., Shen M., Pieper U., Sali A. Comparative protein structure modeling with modeller. Curr. Protoc. Protein Sci. 2007, 50(2.9.):1-31.
28. Sali A., Blundell T.L. Comparative protein modelling by satisfaction of spatial restraints. J. Mol. Biol. 1993, 234:779-815.
29. Shen M.Y., Sali A. Statistical potential for assessment and prediction of protein structures. Protein Sci. 2006, 15:2507-2512.
30. de Amorim H.L., Netz P.A., Guimarães J.A. Thrombin allosteric modulation revisited: a molecular dynamics study. J. Mol. Model. 2010, 16:725-735.
31. Tonjum T., Welty D.B., Jantzen E., Small P.L. Differentiation of Mycobacterium ulcerans, M. marinum, and M. haemophilum: mapping of their relationships to M. tuberculosis by fatty acid profile analysis, DNA-DNA hybridization, and 16S rRNA gene sequence analysis. J. Clin. Microbiol. 1998, 36:918-925.
32. Fullam E., Kawamura A., Wilkinson H., Abuhammad A., Westwood I., Sim E. Comparison of the arylamine N-acetyltransferase from Mycobacterium marinum and Mycobacterium tuberculosis. Protein J. 2009, 28:281-293.
33. Sandy J., Holton S., Fullam E., Sim E., Noble M. Binding of the anti-tubercular drug isoniazid to the arilamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 2005, 14:775-782.
34. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
35. Bowie J.U., Luthy R., Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science 1991, 253:164-170.
36. Colovos C., Yeates T.O. Verification of protein structures: patterns of nonbonded atomic interactions. Protein Sci. 1993, 2:1511-1519.
37. Wu H., Dombrovsky L., Tempel W., Martin F., Loppnau P., Goodfellow G.H., Grant D.M., Plotnikov A.N. Structural basis of substrate-binding specificity of human arylamine N-acetyltransferases. J. Biol. Chem. 2007, 282:30189-30197.
38. Mushtaq A., Payton M., Sim E. The COOH terminus of arylamine N-acetyltransferase from Salmonella typhimurium controls enzymic activity. J. Biol. Chem. 2002, 277:12175-12181.
39. van Doorn H.R., de Haas P.E.W., Kremer K., Vandenbroucke-Grauls C.M.J., Borgdorff M.W., van Soolingen D. Public health impact of isoniazid-resistant Mycobacterium tuberculosis strains with a mutation at amino-acid position 315 of katG: a decade of experience in The Netherlands. Clin. Microbiol. Infect. 2006, 12:769-775.
40. Sikora A.L., Frankel B.A., Blanchard J.S. Kinetic and chemical mechanism of arylamine n-acetyltransferase from Mycobacterium tuberculosis. Biochemistry 2008, 47:10781-10789.
41. Brudey K., Driscoll J.R., Rilgouts L., Prodinger W.N., Gori A., Al-Hajoi S.A., Allix C., Aristimuno L., et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 2006, 6.
42. Engh R.A., Huber R. Accurate bond and angle parameters for X-ray protein structure refinement. Acta Crystallogr. 1991, 47:392-400.